Abstract: Methods and systems described herein concern machine-learning-assisted materials discovery. One embodiment selects a candidate sample set including a plurality of compositions and performs the following operations iteratively: (1) selects an acquisition sample set, (2) performs a dark electrocatalyst experiment or a photo-electrocatalyst experiment on the compositions in the acquisition sample set to determine one or more properties, (3) trains a machine learning model using the one or more properties, and (4) predicts, based at least in part on one or more outputs of the machine learning model, the one or more properties for one or more compositions in a test sample set including compositions on which an experiment has not yet been performed. When one or more predetermined termination criteria have been satisfied, the embodiment also identifies one or more compositions in the candidate sample set for which the one or more properties satisfy predetermined performance criteria.

Abstract: Methods and systems described herein concern machine-learning-assisted materials discovery. One embodiment selects a candidate sample set including a plurality of compositions and performs the following operations iteratively: (1) selects an acquisition sample set, (2) performs a dark electrocatalyst experiment or a photo-electrocatalyst experiment on the compositions in the acquisition sample set to determine one or more properties, (3) trains a machine learning model using the one or more properties, and (4) predicts, based at least in part on one or more outputs of the machine learning model, the one or more properties for one or more compositions in a test sample set including compositions on which an experiment has not yet been performed. When one or more predetermined termination criteria have been satisfied, the embodiment also identifies one or more compositions in the candidate sample set for which the one or more properties satisfy predetermined performance criteria.

Abstract: A composition for treating, controlling, reducing, ameliorating, or preventing allergy comprises a dissociated glucocorticoid receptor agonist (“DIGRA”), a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable ester thereof. The composition can comprise an anti-allergic medicament and/or an additional anti-inflammatory agent and can be formulated for topical application, injection, or implantation. The anti-allergic medicament can comprise an antihistamine, a mast-cell stabilizer, a leukotriene inhibitor, an immunomodulator, an anti-IgE agent, or a combination thereof.

Abstract: The selective cyclooxygenase-2 inhibitory drug celecoxib is provided in amorphous form. Also provided is a celecoxib drug substance wherein the celecoxib is present, in at least a detectable amount, as amorphous celecoxib. Also provided is a celecoxib-crystallization inhibitor composite comprising particles of amorphous celecoxib or a celecoxib drug substance of the invention in intimate association with one or more crystallization inhibitors, for example polymers. Also provided is a pharmaceutical composition comprising such a celecoxib-crystallization inhibitor composite and one or more excipients. Also provided are processes for preparing amorphous celecoxib, a celecoxib drug substance of the invention, a celecoxib-crystallization inhibitor composite of the invention, and a pharmaceutical composition of the invention.

Abstract: The selective cyclooxygenase-2 inhibitory drug celecoxib is provided in amorphous form. Also provided is a celecoxib drug substance wherein the celecoxib is present, in at least a detectable amount, as amorphous celecoxib. Also provided is a celecoxib-crystallization inhibitor composite comprising particles of amorphous celecoxib or a celecoxib drug substance of the invention in intimate association with one or more crystallization inhibitors, for example polymers. Also provided is a pharmaceutical composition comprising such a celecoxib-crystallization inhibitor composite and one or more excipients. Also provided are processes for preparing amorphous celecoxib, a celecoxib drug substance of the invention, a celecoxib-crystallization inhibitor composite of the invention, and a pharmaceutical composition of the invention.

Abstract: A discrete solid orally deliverable pharmaceutical dosage form comprises a plurality of zones, wherein (a) at least one zone comprises an NSAID; (b) at least one zone, other than a zone comprising the NSAID, comprises HPMC having dispersed therein a prostaglandin type compound in a form of a substantially water-free solid dispersion; (c) the plurality of zones are spatially arranged such that, if there is only one NSAID-containing zone and one prostaglandin-containing zone, these zones are arranged other than as a core and mantle respectively separated by an enteric coating layer; and (d) the HPMC comprises a fraction having particle size smaller than about 53 ?m, said fraction exhibiting, upon dissolution in C02-free purified water to form a 1% weight/volume solution, a pH not lower than about 4. An assay method is also provided for selecting suitable lots of HPMC for use in preparing such a dosage form.